-
-
-
-
-
-
-
Anaptysbio (ANAB) Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe GPP
-
-
-
-
-
-
-
AnaptysBio Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option
-
-
-
-
-
-
-
AnaptysBio Announces Proposed Public Offering of Common Stock
68,144 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

